Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 527

Banks, BHP, RIO, CSL and the tyranny of size

This is an edited transcript of a webinar hosted by Schroders. Part II features Natalie Morcos, Head of Product, Solutions, and Client Service with Justin Halliwell, Head of Research in Australian Equities, and Dr Sally Warneford, Equity Analyst. Part I, featuring Natalie Morcos with Martin Conlon, Head of Australian Equities, can be viewed here.

Natalie Morcos: We hold [RIO and BHP]. Both very similar in iron ore and copper. Can you share with us your current views on these stocks?

Justin Halliwell: The first thing to say is the companies have never been more similar. If you reflect back, say, 10 years ago, BHP still had the South32 assets, and they had petroleum. And in the last 10 years, they've done the South32 demerger, and they've also demerged the petroleum assets. So, now, about two-thirds of each company is iron ore. Those assets go through cycles. Sometimes the costs are a bit lower. Sometimes the profits are a bit higher. But by and large, they are identical. BHP produces a little bit more at a lower profitability, but the net dollars of profit are almost identical. 

Then they both own a share in Escondida, which is the largest copper mine in the world. And so, by that stage, you're almost at three quarters of the valuation for both businesses are identical. And so, we're really arguing around the tail. They both have more copper. BHP has a bigger extra copper business than Rio. But really, the difference is coking coal for BHP versus aluminum for Rio Tinto.

And we own both, but we're underweight BHP and we're overweight Rio. One reason is our outlook for those two commodities. You can see on the chart [below], and where the prices are today, Rio's aluminum business is unquestionably one of the best in the world. It's powered by green energy. And we think over time, not only with aluminum price rising, as I mentioned earlier, but also the green energy, you're going to get either carbon getting priced into commodity prices, so the price goes even higher, or you get green credits, one or the other green premiums, one way or another, Rio's aluminum business will make a lot more money. And you can see at the moment, it's providing a 4% return on capital. Now, look at the iron ore businesses there, they're generating 60% to 70% return on capital.

Source: BHP RIO, Schroders

These iron ore businesses are making supernormal profits. And we think that has to correct. It will impact both of them. But also coking coal prices are elevated at the moment. But obviously, with the focus on decarbonisation, coking coal is the source of carbon. So, over time, that's going to have to come out of the production of steel. And therefore, as you look forwards, the demand for coking coal is not as strong as for aluminum. So, we think, well it's pretty clear that we want to be in green aluminum versus coking coal, and hence the difference in positions. And also, having said, they're so similar, Rio is a $100 billion company, BHP is $150 billion company.

Morcos: Turning to banks, Justin, with rising bad debts expected, has our view on banking stocks changed? And how do our local banks compare to the global banks in particular?

Halliwell: We've been on the more cautious side for a while. And the reason for that is really around when you look back over the last two decades, credit has ballooned. There's been huge, huge credit growth and we think that's over. So, that's really, if you think about what we'd call revenue for an industrial, for a bank, credit is the volume and then the NIM is the price. NIMs are under pressure due to competitive forces. Even if nothing else changes, we think they're pretty dull and boring and there are better places to be, especially with the looming threat of bad debts.

Now, to be fair, to date, they've surprised us and everyone on the fact that they've stayed very low. But clearly, the potential pressure on the consumer, the mortgage cliff and the like, there's still the risk around bad debts. And then, also looming in the background, is he threat of increased taxes on banks, as seen in Europe. It makes us pretty cautious about the outlook for profits.

And then, there's this chart to the point about how they trade against the international peers.

Source: Refinitiv, Company data

You can see here, especially on the right-hand charts, the best one to look at is, for a given ROE, which is the X-axis, the Australian banks, in particular CBA and Macquarie, look very expensive, not only relative to the domestic peers but the international peers. So, there are key underweights in the sector.

Morcos: [Sally], I'm keen to get your current views on CSL.

Sally Warneford: Yes, I wrote my very first report on CSL back in 1994 for the IPO and the share price was $2.30 and the market cap was about $130 million. Since then, it split its shares three times. So, that share price was actually $0.77. Now, it's something like $270 and its market cap is something like $130 billion, which makes it about the 18th largest pharmaceutical company in the world. That's been an extraordinary journey and it's been an incredible performance by the company and the management team over time.

But if we have a look at the chart where the dark blue shows the share price performance, and it's been marking time for a number of years now. And then, the green line shows us the return, so the earnings before interest and tax that you get for the invested capital, which is the net assets plus the net debt.

Source: Schroders

You can see where they've made large capital raisings and acquisitions. For example, in 2000, they bought the Swiss Red Cross, and they raised equity then. And then, again in 2003-2004, they bought Aventis Behring, and they raised equity then. And then, going forward, it took another many years before they made another acquisition which was the flu vaccine business of Novartis in about 2015. So, you can see some step changes in returns when you have some new equity coming in or a loss-making new business. But that doesn't get away from that steady downwards trend in returns despite the great success of the flu vaccine business.

And this is where you're seeing the problem of being such a large company. New investments have come with large amounts of goodwill and also intangible assets in the form of intellectual property. So, it's getting a lot harder for CSL to grow. And people invest in CSL for its growth, and that growth is coming at a cost, and that cost is more acquisitions, more goodwill in the balance sheet and more intangible assets in the balance sheet. And CSL has to try and generate a meaningful return on those investments for shareholders in order to justify being the number 18 market cap pharmaceutical company in the world.

Morcos: What about Ramsay Health Care? This reporting season, we saw them halve their dividend. Can you share with us your current views on Ramsay?

Warneford: When we were talking about COVID earlier, Ramsay was a classic example of a COVID loser. They were forced by governments to close their hospitals and that meant that they couldn't earn any money. They were relying on grants for governments to cover their fixed costs, and they were forced to treat COVID patients, which is good. We needed that at the time, but not good for Ramsay's ongoing business.

We're seeing a big hangover from COVID and that is labour shortages, elevated labour costs, labour inefficiencies because there's been increased absenteeism and people wanting reduced hours. And then, we've got this very modest recovery, slower than I would have thought, of volumes of elective surgeries which is their bread and butter around the world. The share price has been derated substantially.

And then, unfortunately, Ramsay is one of those companies with significant gearing in the balance sheet and that has meant that interest costs with the rising interest rates have been very substantial and depressed the bottom-line profit for the company. That is why we've seen that fall in the dividend.

But with this gradual return in activity, we expect that the profitability will gradually return as will the cash flows to pay down the debt. So, Ramsay should continue to improve from here.

Morcos: ResMed, another beneficiary, but this time of the growing trend in sleep apnea. Now, obviously, with the correlation between sleep apnea and obesity the question here is around whether weight loss solutions such as Ozempic have actually going to become a threat to a company like ResMed. 

Warneford: Yes, it's a fascinating situation. ResMed has recently been the beneficiary of its major competitor Philips being absent from the market due to a recall, but there was a COVID-related shortages of components. But over the last two years something that's been weighing on investors' minds has been the impact of the new class of GLP-1 agonist drugs for diabetes and now for weight loss or obesity. And the ones that spring to mind are the brand names Ozempic, Wegovy, both from Novo Nordisk in Denmark and then Mounjaro from Eli Lilly, which is currently in clinical trials. These drugs are amazing. They are able to generate weight losses of 10% to 30% and they're a simple injection. One of the problems that has been there have been shortages of the drugs. Eli Lilly and Novo Nordisk just haven't been able to keep up with the demand.

Now, why is this important for ResMed? It's important because obesity is probably the single biggest risk factor for obstructive sleep apnea, which is what ResMed's machines treat. If you can cure obesity, we then in turn cure obstructive sleep apnea. And that's the question that investors are wrestling with. Now, I don't believe that that will be the case because something like 15% to 40% of obstructive sleep apnea cases are not solely due to obesity, and in addition to that, the obesity drugs are drugs for life. The weight piles back on if you stop them. So, that will be an issue.

 

This is an edited transcript of a webinar hosted by Schroders, a sponsor of Firstlinks. Part II features Natalie Morcos, Head of Product, Solutions, and Client Service with Justin Halliwell, Head of Research in Australian Equities, and Dr Sally Warneford, Equity Analyst. Part I can be viewed here.

For more articles and papers from Schroders, click here.

 

4 Comments
Peter Care
September 25, 2023

“If we cure obesity, we then in turn cure obstructive sleep apnea.” This implies that Resmed’s business will be wiped out. This is rubbish analysis. While reducing obesity will reduce the amount of sleep apnea, there will still be plenty of business for Resmed. This is because there is a lot of Resmed, Philips and F & P patients who are not obese and only a small minority of people who have sleep apnea have been diagnosed and receiving treatment. It is still a growing market for CPAP machines, until someone invents a better product.

James Gruber
September 25, 2023

Peter, this is a strange critique of the Schroders' analyst. Your quote from Sally is actually her referring to what 'investors' or 'the market' thinks. She then goes on to why she disagrees with the market's assessment of ResMed, and that assessment aligns with your thinking.

D Ramsay
September 25, 2023

Really interesting article thanks.
I don't know how old the data is , but ..........
Given that CBA price today is $100 (near enough) and that is a P/B of 2.25 (by your graph)
Then if it retreated to a P/B of 1 , that would be $80 ?

Or don't PB numbers work proportionally ?

Fund manager
September 21, 2023

Great analysis on BHP vs RIO. Agree that Alumina appears compelling at these levels.

CSL - not so sure. Long-term, you will be proven correct, though margin improvement and capex reductions could lift ROIC for a few years.

 

Leave a Comment:

RELATED ARTICLES

How we have invested during COVID-19

Why August company reporting season was poor

Wilson Asset Management on markets and its new income fund

banner

Most viewed in recent weeks

Raising the GST to 15%

Treasurer Jim Chalmers aims to tackle tax reform but faces challenges. Previous reviews struggled due to political sensitivities, highlighting the need for comprehensive and politically feasible change.

Here's what should replace the $3 million super tax

With Div. 296 looming, is there a smarter way to tax superannuation? This proposes a fairer, income-linked alternative that respects compounding, ensures predictability, and avoids taxing unrealised capital gains. 

100 Aussies: seven charts on who earns, pays, and owns

The Labor government is talking up tax reform to lift Australia’s ailing economic growth. Before any changes are made, it’s important to know who pays tax, who owns assets, and how much people have in their super for retirement.

The rubbery numbers behind super tax concessions

In selling the super tax, Labor has repeated Treasury claims of there being $50 billion in super tax concessions annually, mostly flowing to high-income earners. This figure is vastly overstated.

9 winning investment strategies

There are many ways to invest in stocks, but some strategies are more effective than others. Here are nine tried and tested investment approaches - choosing one of these can improve your chances of reaching your financial goals.

With markets near record highs, here's what you should do with your portfolio

Markets have weathered geopolitical turmoil, hitting near record highs. Investors face tough decisions on valuations, asset concentration, and strategic portfolio rebalancing for risk control and future returns.

Latest Updates

Investment strategies

Finding income in an income-starved world

With term deposit rates falling, bonds holding up but with risks attached, and stocks yielding comparatively paltry sums, finding decent income is becoming harder. Here’s a guide to the best places to hunt for yield.

Economy

Fearful politicians put finances at risk

A tearful Treasury chief, a backbench rebellion, and crashing bonds. What just happened in the UK and why could Australia’s NDIS be headed for the same brutal fiscal reality?

Shares

Investing at market peaks: The surprising truth

Many investors are hesitant to buy into a market that feels like it’s already climbed too far, too fast. But what does nearly a century of market history suggest about investing at peaks?

Shares

Chinese steel - building a Sydney Harbour Bridge every 10 minutes

China's steel production, equivalent to building one Sydney Harbour Bridge every 10 minutes, has driven Australia's economic growth. With China's slowdown, what does this mean for Australia's economy and investments?

Investment strategies

Will stablecoins change the way we pay for things?

Stablecoins have been hyped as a gamechanger for the payments industry. But while they could find success in certain niches, a broader upheaval of Visa and Mastercard's payments dominance looks unlikely.

Infrastructure

An investing theme you can bet on for the next 30 years

Investors view infrastructure as a defensive asset class rather than one with compelling growth prospects. These five tailwinds for demand over the coming decades suggest that such a stance could be mistaken.

Investment strategies

A letter to my younger self: investing through today's chaos

We are trading through one of history's most confounding market environments. One day, financial headlines warn of doomsday scenarios. The next, they celebrate a new golden age. How can investors keep a clear head?

Sponsors

Alliances

© 2025 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.